Abstract:The typical modern lifestyle contributes to the development of many metabolic-related disorders, as exemplified by metabolic syndrome. How to prevent, resolve, or avoid subsequent deterioration of metabolic disturbances and the development of more serious diseases has become an important and much-discussed health issue. Thus, the question of the physiological and pathological roles of thyroid hormones (THs) in metabolism has never gone out of fashion. Although THs influence almost all organs, the liver is one of the most important targets as well as the hub of metabolic homeostasis. When this homeostasis is out of balance, diseases may result. In the current review, we summarize the common features and actions of THs, first focusing on their effects on lipid metabolism in the liver. In the second half of the review, we turn to a consideration of non-alcoholic fatty liver disease (NAFLD), a disease characterized by excessive accumulation of fat in the liver that is independent of heavy alcohol consumption. NAFLD is a growing health problem that currently affects ~25% of the world's population. Unfortunately, there are currently no approved therapies specific for NAFLD, which, if left uncontrolled, may progress to more serious diseases, such as cirrhosis or liver cancer. This absence of effective treatment can also result in the development of non-alcoholic steatohepatitis (NASH), an aggressive form of NAFLD that is the leading cause of liver transplantation in the United States. Because THs play a clear role in hepatic fat metabolism, their potential application in the prevention and treatment of NAFLD has attracted considerable research attention. Studies that have investigated the use of TH-related compounds in the management of NAFLD are also summarized in the latter part of this review. An important take-home point of this review is that a comprehensive understanding of the physiological and pathological roles of THs in liver fat metabolism is possible, despite the complexities of this regulatory axis—an understanding that has clinical value for the specific management of NAFLD.

Cross-talk Between the Thyroid and Liver: a New Target for Nonalcoholic Fatty Liver Disease Treatment.

Thyroid Hormone Receptor:A New Target of Nonalcoholic Fatty Liver Disease

Cross-Talk Between Thyroid Disorders and Nonalcoholic Fatty Liver Disease: From Pathophysiology to Therapeutics

Thyroid Hormone Receptor- Agonists in NAFLD Therapy: Possibilities and Challenges

Thyroid Hormone Receptor-β Agonists in NAFLD Therapy: Possibilities and Challenges

Thyroid Hormone Receptor-beta Agonists in NAFLD Therapy: Possibilities and Challenges

Thyroid hormones as a disease modifier and therapeutic target in nonalcoholic steatohepatitis

Development of Thyroid Hormones and Synthetic Thyromimetics in Non-Alcoholic Fatty Liver Disease

Effects of Thyroid Hormones on Lipid Metabolism Pathologies in Non-Alcoholic Fatty Liver Disease

NAFLD and thyroid function: pathophysiological and therapeutic considerations

Thyroid Hormone Attenuate Nonalcoholic Fatty Liver Disease Via Inducing Autophagy In Rats

Hypothyroidism-Induced Nonalcoholic Fatty Liver Disease (HIN): Mechanisms and Emerging Therapeutic Options

Thyroid Function and Non-Alcoholic Fatty Liver Disease in Hyperthyroidism Patients

Targeting Thyroid Hormone/Thyroid Hormone Receptor Axis: an Attractive Therapy Strategy in Liver Diseases.

The roles of autophagy and thyroid hormone in the pathogenesis and treatment of NAFLD

Regulation of Fatty Acid Composition and Lipid Storage by Thyroid Hormone in Mouse Liver

Association Between Thyroid Function and Nonalcoholic Fatty Liver Disease in Euthyroid Elderly Chinese

Targeting Liver X Receptors for the Treatment of Non-Alcoholic Fatty Liver Disease

Nonalcoholic Fatty Liver Disease: Molecular Pathways and Therapeutic Strategies

Current Therapeutical Approaches Targeting Lipid Metabolism in NAFLD

Emerging targets and potential therapeutic agents in non-alcoholic fatty liver disease treatment